Study S000152

New Onset Type 1 Diabetes: Role of Exenatide

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol (PDF)

Registration

Registration: NCT01269034
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 13
Start: 2010-12
Primary completion: 2017-01-31
Lead sponsor: Albert Einstein College of Medicine
Conditions: Type 1 Diabetes
Interventions: DRUG:Exenatide; DRUG:Rapid and long acting insulin; DRUG:long acting insulin + rapid acting + 1.25 mcg Exenatide
Results posted: TRUE
Secondary identifiers: NIH:3R01DK077166-05S1

Registered primary outcomes

The Role of Exenatide as Compared to Insulin Monotherapy in Reducing Postprandial Hyperglycemia. [February 2013]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.